Cardiovascular toxicity in metastatic prostate cancer treatment: balancing risks, treating consequences
Anno:
2024
INTRODUCTION Enzalutamide inhibits the receptor of androgen hormones. It is administered for treating metastasized prostate cancer. Enzalutamide is known to have a cardiotoxic effect. CASE REPORT A 76 year-old man on-treatment for hypertension and overall good health underwent radical prostatectomy and bilateral ileo-obturator lymphadenectomy in 2021 for prostate cancer….